10-Q: Merck Reports 5% Sales Growth in Q3 2026

Merck & Co., Inc. announced its third-quarter 2026 financial results, showcasing a 5% increase in worldwide sales to $18.1 billion, driven by strong performance in oncology and animal health, despite increased R&D expenses.

Summary

• Merck & Co., Inc. reported worldwide sales of $18.1 billion for the third quarter of 2026, a 5% increase compared to the same period in 2025, and $51.0 billion for the first nine months, a 5% increase.
• The company experienced growth in its oncology and animal health segments, with Keytruda/Keytruda Qlex sales reaching $8.6 billion in Q3.
• Research and development expenses increased significantly to $4.5 billion in Q3 2026, largely due to business development activities including acquisitions of Cidara Therapeutics and Terns Pharmaceuticals.
• Restructuring costs were $184 million in Q3 2026, part of ongoing programs aimed at optimizing operations and achieving cost savings.
• Net income attributable to Merck & Co., Inc. for the nine months ended September 30, 2026, was a loss of $510 million, compared to a net income of $15.3 billion in the prior year period, impacted by acquisition-related charges.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with strong underlying operational performance partially offset by significant R&D investments and ongoing restructuring costs.

Positives

• Worldwide sales increased by 5% to $18.1 billion in Q3 2026 and by 5% to $51.0 billion for the first nine months of 2026.
• Keytruda/Keytruda Qlex sales grew 6% in Q3 2026 to $8.6 billion, driven by increased demand and new indications.
• Animal Health segment sales grew 4% in Q3 2026 and 8% year-to-date, indicating strong performance in both livestock and companion animal products.
• Welireg sales increased by 56% in Q3 2026, demonstrating strong uptake for its approved indications.
• Winrevair sales showed substantial growth, rising 93% in Q3 2026, driven by increased demand and international uptake.

Negatives

• Net income attributable to Merck & Co., Inc. for the nine months ended September 30, 2026, was a loss of $510 million, a significant decrease from $15.3 billion in the prior year period.
• Research and development expenses increased substantially to $26.9 billion in the first nine months of 2026, primarily due to large acquisition-related charges for Terns Pharmaceuticals ($5.7 billion) and Cidara Therapeutics ($9.0 billion).
• Cost of sales increased by 27% in Q3 2026 and 24% year-to-date, impacting gross margin, which declined to 72.9% in Q3 2026 from 77.7% in Q3 2025.
• Sales of Januvia/Janumet declined 39% in Q3 2026 due to generic competition following loss of market exclusivity in the U.S.
• Sales of Lagevrio decreased significantly by 88% in Q3 2026 due to declining COVID-19 cases and the expected termination of its U.S. Emergency Use Authorization.

Risks

• Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide.
• The Inflation Reduction Act (IRA) has introduced significant changes to Medicare, including government price-setting for certain drugs, which could negatively impact future pricing and revenue.
• Ongoing litigation, including patent disputes and product liability lawsuits, could result in significant financial liabilities or shortened periods of exclusivity.
• The company faces competition from generic and biosimilar products, which can lead to significant sales declines upon loss of market exclusivity.
• The U.S. Department of Justice is investigating Merck's diversity, equity, and inclusion programs and practices related to federal contracts, and its price reporting under the Medicaid Drug Rebate Program.

Future Outlook

The company anticipates that ongoing healthcare cost containment measures, government price setting under the IRA, and competition from generics and biosimilars will continue to negatively affect sales and profits. However, growth is expected from key products like Keytruda and Welireg, and new product launches.

Management Comments

• Robert M. Davis certifies that the report does not contain any untrue statement of a material fact and that financial statements fairly present the company's financial condition.
• Caroline Litchfield certifies that the report does not contain any untrue statement of a material fact and that financial statements fairly present the company's financial condition.

Industry Context

StockSavvy.ai notes that Merck's performance reflects broader industry trends, including intense R&D investment for pipeline advancement, significant M&A activity to acquire novel therapies, and increasing pricing pressures due to healthcare reforms and competition.

Comparison to Industry Standards

• Merck's sales growth of 5% in Q3 2026 is in line with or slightly above the average growth rates reported by large pharmaceutical companies in the current market environment, which is characterized by strong performance in oncology and immunology but pressure on established products.
• The significant increase in R&D expenses, particularly due to acquisitions like Terns and Cidara, aligns with industry-wide strategies to invest heavily in pipeline development and acquire innovative assets, though the scale of these investments is substantial.
• The decline in sales for Januvia and Janumet due to generic competition is a common challenge faced by many pharmaceutical companies as blockbuster drugs approach patent expiry.
• The company's focus on oncology, particularly with Keytruda, is a key differentiator, as oncology remains a high-growth area within the pharmaceutical industry, with many competitors also heavily invested in this segment.

Legal Proceedings

• Merck is a defendant in product liability lawsuits related to Dr. Scholls foot powder and Gardasil/Gardasil 9.
• The company received Civil Investigative Demands from the DOJ regarding diversity, equity, and inclusion programs and price reporting under the Medicaid Drug Rebate Program.
• Merck is involved in patent litigation concerning Keytruda, Lenvima, Lynparza, Capvaxive, and subcutaneous pembrolizumab.
• A putative class action lawsuit (Cronin v. Merck & Co., Inc., et al.) alleges misleading statements regarding demand for Gardasil/Gardasil 9 in China.
• RotaTeq Antitrust Litigation alleges violations of federal and state antitrust laws and consumer protection laws.
• Bravecto Litigation involves claims of neurological events in dogs and cats and alleged violations of consumer fraud statutes.

Stakeholder Impact

• Shareholders may see mixed impacts from sales growth and increased R&D/restructuring costs, with a net loss reported year-to-date.
• Employees may be affected by ongoing restructuring programs involving position eliminations.
• Customers (healthcare providers, distributors) will continue to face pricing pressures, potentially impacting their own margins.
• Creditors are exposed to the company's debt obligations, which remain substantial.

Next Steps

• Continue to advance pipeline candidates through clinical development and regulatory review.
• Integrate recently acquired companies (Cidara, Terns, TARGAN) and realize synergies.
• Monitor and respond to evolving pricing and reimbursement landscapes globally.
• Execute on restructuring programs to achieve targeted cost savings.

Key Dates

Recommendation

Merck demonstrates strong operational performance with solid sales growth driven by key products like Keytruda and a growing Animal Health segment. However, the significant increase in R&D expenses due to major acquisitions, coupled with ongoing restructuring costs and the net loss reported year-to-date, introduces considerable uncertainty. The increasing pricing pressures from regulatory actions like the IRA and generic competition also pose risks. While the long-term pipeline is promising, the current financial results and near-term headwinds warrant a cautious 'hold' stance.

Keywords

pharmaceuticals, oncology, animal health, Keytruda, vaccines, R&D, acquisitions, financial results